Clarity Pharmaceuticals (ASX:CU6): What Does FDA Breakthrough Designation Change?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Clarity Pharmaceuticals (ASX:CU6): What Does FDA Breakthrough Designation Change?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clarity Pharmaceuticals (ASX:CU6) received an FDA Breakthrough Therapy designation.
The designation concerns copper-64 SAR-bisPSMA PET imaging for suspected prostate cancer recurrence.
The CLARIFY Phase III trial reached its planned 383-participant target.
AMPLIFY and CLARIFY topline data are anticipated in the first half of 2027.

Clarity Pharmaceuticals Limited (ASX:CU6) develops investigational radiopharmaceutical products for cancer imaging and treatment, with a clinical pipeline built around copper isotopes and its SAR technology. On 12 November 2026, CU6 shares were priced at AUD 2.12, up 27.71% in the trading session. The company announced on that date that the US Food and Drug Administration had granted Breakthrough Therapy Designation to its copper-64 SAR-bisPSMA PET imaging agent for a specified use in suspected recurrent prostate cancer, while pivotal trials continue.

Copper-Based Cancer Imaging and Therapy

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage company rather than a supplier of approved commercial products from its principal pipeline. Its SAR-bisPSMA program targets prostate-specific membrane antigen in prostate cancer and uses different copper isotopes for diagnostic imaging and therapeutic development. The diagnostic candidate copper-64 SAR-bisPSMA is being evaluated in positron emission tomography, while copper-67 SAR-bisPSMA is being studied as a treatment. Other development programs include SARTATE and SAR-Bombesin. Their clinical indications, trial stages and regulatory assessments are distinct, so progress in one program cannot be treated as approval of the others.

FDA Breakthrough Therapy Designation

On 12 November 2026, Clarity Pharmaceuticals (ASX:CU6) reported that the FDA had granted Breakthrough Therapy designation to copper-64 SAR-bisPSMA for PET imaging of PSMA-positive lesions in men with suspected recurrent prostate cancer indicated by elevated prostate-specific antigen. The designation can provide additional interaction with regulators and an expedited development pathway. It is not Marketing approval. The company cited evidence from its Co-PSMA and COBRA studies, as well as real-world observations, in support of the decision. These findings remain separate from the results expected from ongoing Phase III programs.

CLARIFY and AMPLIFY Trial Status

Clarity Pharmaceuticals (ASX:CU6) stated that both the CLARIFY and AMPLIFY registrational Phase III trials had completed recruitment and moved into patient follow-up. In October, CLARIFY had dosed its target 383 participants. That study examines the imaging agent in patients with high-risk prostate cancer before radical prostatectomy, while AMPLIFY addresses suspected biochemical recurrence. The company anticipated topline results from both trials in the first half of calendar 2027. Trial completion, diagnostic performance and subsequent regulatory review remain separate steps; the current status should not be interpreted as an approval outcome.

SECuRE Program and Development Context

Clarity Pharmaceuticals (ASX:CU6) also reported in October that the main expansion group in its Phase I/IIa SECuRE study had reached its recruitment target of 16 participants. The enrolled patients have metastatic castration-resistant prostate cancer and are being assessed for safety and efficacy of copper-67 SAR-bisPSMA at a specified dosing schedule. An additional combination-treatment group involving enzalutamide remained under recruitment. These therapeutic trials involve a different isotope and clinical purpose from the copper-64 diagnostic program and require their own evidence before regulatory decisions can be made.

Regulatory and Financial Risks

As Clarity Pharmaceuticals (ASX:CU6) remains in clinical development, future outcomes depend on trial data, safety assessments, Manufacturing readiness and regulatory decisions. Breakthrough designation does not eliminate those requirements or guarantee that products will reach patients commercially. The November announcement did not disclose an immediate sales contribution or Earnings uplift attributable to the designation. Investors following the operational timetable can monitor patient follow-up, release of pivotal study results and any subsequent formal submissions to health authorities, while keeping diagnostic and therapeutic programs distinct.

Key Insights

Clarity Pharmaceuticals (ASX:CU6) has obtained a US regulatory development designation for a prostate cancer imaging agent and completed recruitment in two Phase III studies. The designation may change the regulatory interaction process but does not constitute product approval. The principal future evidence points are the anticipated 2027 study results, regulatory filings and continuing development of the separate treatment program.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.